ACTINOGEN MEDICAL LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.027 AUD | -3.57% |
|
-15.62% | +22.73% |
| 07/05 | Actinogen Medical Lodges Prospectus for Nearly AU$4 Million Entitlement Offer | MT |
| 03/05 | Actinogen Medical Raising Up to AU$8.9 Million for Advancing Trial, Working Capital; Shares Fall 24% | MT |
Valuation
| Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 11.19 | 24.56 | 215.9 | 89.78 | 72.65 | 65.15 | - |
| Enterprise Value (EV) 1 | 3.556 | 19.91 | 215.9 | 73.58 | 64.19 | 67.04 | 118.4 |
| P/E ratio | -1.13 x | -4.65 x | -47.1 x | -9.23 x | -6.76 x | -3.5 x | -1.75 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 2.3 x | 6.8 x | - | 24.4 x | 13.8 x | 8.46 x | 3.21 x |
| EV / Revenue | 0.73 x | 5.51 x | - | 20 x | 12.2 x | 8.71 x | 5.83 x |
| EV / EBITDA | -0.39 x | -4.07 x | - | -8.09 x | -6.29 x | -4.05 x | -3.36 x |
| EV / FCF | - | - | - | - | -7.35 x | -3.38 x | -2.3 x |
| FCF Yield | - | - | - | - | -13.6% | -29.6% | -43.4% |
| Price to Book | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 11,19,231 | 11,16,231 | 16,60,559 | 17,95,644 | 18,16,252 | 23,26,921 | - |
| Reference price 2 | 0.0100 | 0.0220 | 0.1300 | 0.0500 | 0.0400 | 0.0280 | 0.0280 |
| Announcement Date | 16/08/19 | 26/08/20 | 30/08/21 | 25/08/22 | 30/08/23 | - | - |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 4.863 | 3.61 | - | 3.681 | 5.255 | 7.7 | 20.3 |
| EBITDA 1 | -9.049 | -4.889 | - | -9.092 | -10.21 | -16.54 | -35.22 |
| EBIT 1 | -9.403 | -5.302 | - | -9.492 | -10.62 | -16.06 | -35.45 |
| Operating Margin | -193.36% | -146.84% | - | -257.86% | -202.08% | -208.55% | -174.63% |
| Earnings before Tax (EBT) 1 | -9.888 | -5.331 | - | -9.497 | -10.75 | -16.65 | -38.18 |
| Net income 1 | -9.888 | -5.331 | -3.915 | -9.497 | -10.75 | -16.65 | -38.18 |
| Net margin | -203.33% | -147.64% | - | -258% | -204.63% | -216.21% | -188.08% |
| EPS 2 | -0.008880 | -0.004730 | -0.002760 | -0.005420 | -0.005920 | -0.008000 | -0.0160 |
| Free Cash Flow 1 | - | - | - | - | -8.735 | -19.85 | -51.38 |
| FCF margin | - | - | - | - | -166.23% | -257.84% | -253.08% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 16/08/19 | 26/08/20 | 30/08/21 | 25/08/22 | 30/08/23 | - | - |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: June | 2023 S1 |
|---|---|
| Net sales 1 | 1.14 |
| EBITDA | - |
| EBIT 1 | -7.345 |
| Operating Margin | -644.28% |
| Earnings before Tax (EBT) | - |
| Net income 1 | -7.439 |
| Net margin | -652.51% |
| EPS | - |
| Dividend per Share | - |
| Announcement Date | 22/02/23 |
1AUD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | 1.89 | 53.3 |
| Net Cash position 1 | 7.64 | 4.65 | - | 16.2 | 8.46 | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | -0.1142 x | -1.512 x |
| Free Cash Flow 1 | - | - | - | - | -8.73 | -19.9 | -51.4 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex 1 | - | 0.02 | - | 0 | 0.04 | 0.67 | 1.08 |
| Capex / Sales | - | 0.63% | - | 0.08% | 0.7% | 8.73% | 5.33% |
| Announcement Date | 16/08/19 | 26/08/20 | 30/08/21 | 25/08/22 | 30/08/23 | - | - |
1AUD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +22.73% | 4.61Cr | |
| +26.37% | 4.5TCr | |
| -1.01% | 4.26TCr | |
| +46.00% | 4.18TCr | |
| -5.31% | 2.9TCr | |
| +9.34% | 2.61TCr | |
| -21.69% | 1.9TCr | |
| +6.23% | 1.28TCr | |
| +26.99% | 1.21TCr | |
| -3.38% | 1.18TCr |
- Stock Market
- Equities
- ACW Stock
- Financials Actinogen Medical Limited